Palbociclib + Binimetinib for Pancreatic Cancer
Trial Summary
Binimetinib has been studied for safety in humans, particularly in patients with advanced solid tumors, and its maximum tolerated dose was determined in a phase 1 study. However, specific safety data for the combination of Palbociclib and Binimetinib in humans is not provided in the available research.
25789The trial requires that you stop taking any cancer-directed therapy at least 28 days before joining, except for hormonal therapy, which can be taken up to 14 days before. Additionally, you must stop taking strong CYP3A4 inhibitors or inducers and P-glycoprotein inhibitors or inducers 14 days before starting the trial.
The combination of Palbociclib and Binimetinib is unique because it targets specific pathways involved in cancer cell growth, with Palbociclib inhibiting cell cycle progression and Binimetinib blocking MEK enzymes, which are part of a signaling pathway often active in cancers. This dual approach may offer a novel way to tackle pancreatic cancer compared to standard treatments.
123510Research shows that binimetinib, a MEK inhibitor, has shown effectiveness in treating certain cancers like melanoma and colorectal cancer, especially when combined with other targeted therapies. Additionally, a case report indicated a positive tumor response in pancreatic cancer when a similar MEK inhibitor was used with a BRAF inhibitor.
245610Eligibility Criteria
This trial is for patients with RAS-mutated cancers, such as low grade serous ovarian cancer and pancreatic cancer, who have no curable treatment options. Participants must have measurable disease, be able to undergo a biopsy, and not have had prior MEK inhibitor or CDK4/6 inhibitor therapy (with exceptions for certain mutations). They should also meet all ComboMATCH Registration Protocol criteria.Inclusion Criteria
Participant Groups
- Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- Unresectable or metastatic melanoma with a BRAF V600 mutation
- Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- Unresectable or metastatic melanoma with a BRAF V600 mutation